A 3-day-old male neonate born to non-consanguineous Indian parents presents with poor feeding, lethargy, and a characteristic 'musty' or 'mousy' odour in urine. Serum phenylalanine is 1240 µmol/L (normal <120 µmol/L). Tandem mass spectrometry confirms elevated phenylalanine with normal tyrosine levels. What is the most appropriate immediate next step in management?

Explanation

## Immediate Management of Neonatal PKU This neonate presents with **classic phenylketonuria (PKU)**: serum phenylalanine 1240 µmol/L (>10× normal), normal tyrosine, and the pathognomonic 'musty/mousy' urine odour caused by phenylacetate accumulation. Tandem mass spectrometry (TMS) has already confirmed the biochemical diagnosis. ### Why Start Dietary Restriction Immediately? **Key Point:** When TMS confirms markedly elevated phenylalanine (>1200 µmol/L) with normal tyrosine in a symptomatic neonate, the **most appropriate immediate next step is to start a phenylalanine-restricted diet and low-phenylalanine formula without delay.** Every day of untreated hyperphenylalaninaemia causes irreversible neuronal injury. Current ACMG/ESPKU guidelines state that dietary treatment should begin **as soon as the diagnosis is biochemically confirmed**, which TMS has already accomplished here. **High-Yield:** The threshold for immediate dietary intervention is phenylalanine >600 µmol/L on confirmed testing. At 1240 µmol/L this neonate is well above that threshold. Waiting for additional confirmatory tests (urine organic acids, plasma amino acid profile) before starting treatment is NOT the standard of care when TMS already shows unambiguous classic PKU biochemistry. ### Role of Additional Testing - **Plasma amino acid quantitation and urine organic acids** are performed **concurrently** with or **after** initiating dietary therapy — not as a prerequisite. - **BH₄ loading test** can be done after dietary stabilisation to identify BH₄-responsive PKU; it does not delay initial dietary management. - **Liver biopsy** (Option D) has no role in neonatal PKU diagnosis. - **IV saline + 48-hour monitoring** (Option A) is inappropriate and dangerous — it delays treatment with no clinical benefit. ### Management Algorithm (ACMG 2014 / ESPKU 2017) 1. TMS confirms Phe >600 µmol/L → **Start low-Phe formula immediately** 2. Simultaneously obtain plasma amino acids + urine organic acids + BH₄ loading test 3. Target serum Phe 120–360 µmol/L (2–6 mg/dL) in infancy 4. Lifelong dietary monitoring; consider sapropterin (BH₄) if loading test positive **Clinical Pearl:** The window for preventing intellectual disability in PKU is narrow. Treatment initiated within the first 2 weeks of life is associated with normal cognitive outcomes; delays beyond 3–4 weeks result in measurable IQ loss. The principle is **treat first, refine diagnosis concurrently** — not confirm first, treat later. **Mnemonic — PKU Neonatal Action:** **TREAT-THEN-TEST** - **T**MS confirms → **T**reat immediately with low-Phe formula - **R**efine with plasma amino acids + BH₄ loading concurrently - **E**nsure Phe targets are met within days [cite: ACMG PKU Guidelines 2014; Blau N et al., Lancet 2010; Harrison's Principles of Internal Medicine 21e, Ch 402]